W
Weidong Jia
Publications - 3
Citations - 344
Weidong Jia is an academic researcher. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 1, co-authored 2 publications receiving 13 citations.
Papers
More filters
Journal ArticleDOI
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Zhenggang Ren,Jianming Xu,Yuxian Bai,Aibing Xu,Shundong Cang,Chengyou Du,Qiu Li,Yinying Lu,Yajin Chen,Yabing Guo,Zhendong Chen,Baorui Liu,Weidong Jia,Jian Wu,Junye Wang,Guoliang Shao,Bixiang Zhang,Yunfeng Shan,Zhiqiang Meng,Jianbing Wu,Shanzhi Gu,Wei Yang,Chao Liu,Xuetao Shi,Zhenyuan Gao,Tao Yin,Jiuwei Cui,Ming Huang,Baocai Xing,Yilei Mao,Gao-Jun Teng,Yanru Qin,Jinhai Wang,Feng Xia,Guowen Yin,Yong Yang,Mingxia Chen,Yan Wang,Hui Zhou,Jia Fan +39 more
TL;DR: The phase 2-3 ORIENT-32 study as discussed by the authors compared sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma.
Journal ArticleDOI
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Jian Zhou,Hui-Chuan Sun,Zheng Wang,Wenming Cong,Mengsu Zeng,Weiping Zhou,Ping Bie,Lianxin Liu,Tian-Fu Wen,Ming Kuang,Guohong Han,Zhiping Yan,Ruibao Liu,Ligong Lu,Zhenggang Ren,Zhaochong Zeng,Ping Liang,C. H. Lin,Min Chen,Fuhua Yan,Wenping Wang,Jin-Xiu Hou,Yuan Ji,Jingping Yun,Xueli Bai,Dingfang Cai,Weixia Chen,Yongjun Chen,Wenwu Cheng,Shuqun Cheng,Chaoliu Dai,Wen-Tao Guo,Yabing Guo,Baojin Hua,Xiao-Wu Huang,Weidong Jia,Qiu Li,Tao Li,Xun Li,Yaming Li,Yexiong Li,Jun Liang,Changquan Ling,Tian Liu,Xiu-Feng Liu,Shichun Lu,Guoyue Lv,Yilei Mao,Zhiqiang Meng,Tao Peng,Weixin Ren,Hongcheng Shi,Guoming Shi,Ming Quan Shi,Tianqiang Song,Kaishan Tao,Jianhua Wang,Kui Wang,Lu Wang,Wentao Wang,Xiaoying Wang,Zhiming Wang,Bo Xiang,B. Xing,Jianming Xu,Jiamei Yang,Jianyong Yang,Yefa Yang,Yunke Yang,Shenglong Ye,Zhenyu Yin,Yong Zeng,Bixiang Zhang,Bo-Heng Zhang,Leida Zhang,Shuijun Zhang,Ti Zhang,Yanqiao Zhang,Min Zhao,Yongfu Zhao,Honggang Zheng,Ledu Zhou,Jiye Zhu,Kangshun Zhu,Rong Liu,Ying-Hong Shi,Yongsheng Xiao,Lan Zhang,Chun Yang,Zhifeng Wu,Zhi Dai,Minshan Chen,Jianqiang Cai,Weilin Wang,Xiujun Cai,Qiang Li,Feng Shen,Shukui Qin,Gao-Jun Teng,Jiahong Dong,Jiali Fan +100 more
TL;DR: Wang et al. as discussed by the authors proposed a new guideline for primary liver cancer in China, which aims to encourage the implementation of evidence-based practice, and improve the national average five-year survival rate for patients with liver cancer.
Journal ArticleDOI
Real-world data on the clinicopathological traits and outcomes of hospitalized liver hemangioma patients: a multicenter study
Tengqian Tang,Xishu Wang,Yilei Mao,Jing Li,Tian-Fu Wen,Weidong Jia,Yongjun Chen,Tao Peng,Lingxiao Liu,Rui-Fang Fan,Kuansheng Ma,Feng Xia +11 more
TL;DR: Most patients in this study who were hospitalized for hepatic hemangioma did not meet the indications for requiring treatment, and a new classification system is needed to standardize the diagnosis of this condition.